AVAX Eyes $15 as Treasury Debt Hits Zero, but $8.33 Stands in the Way

$AVAX has a fresh corporate development to build on, but its price chart isn’t making things easy. Avalanche treasury company $AVAX One has eliminated its remaining $970,000 in convertible debt, bringing its outstanding balance to zero. Yet $AVAX trades near $8.26, just below a critical resistance level that could determine its next move.

$AVAX One Clears Debt and Expands Share Buybacks

The company’s latest balance-sheet update marks a significant reduction in debt. $AVAX One removed more than $14.9 million in debt during the third quarter before eliminating its remaining $970,000.

That’s not the only development. In October, the company repurchased 710,000 shares at an average price of $5.46. Total buybacks since November 2025 have reached nearly 1.5 million shares.

There’s still considerable room in the program. Approximately $30.4 million remains available under its $40 million share repurchase authorization.

$AVAX Price Faces an $8.33 Resistance Problem

Now comes the less comfortable part. $AVAX is trading around $8.26, slightly below former support at $8.328, which has become an important level to reclaim.

The chart scenario allows for another decline toward the low $7 range before a potential recovery. However, buyers need a daily close above $8.328, followed by a successful retest.

Breaking the descending trendline is another requirement. Without that confirmation, talk of a $15 recovery remains speculative.

Can $AVAX Push Toward Its $14.93 Target?

If the recovery gains traction, $10.511 and $12.043 are the next resistance levels. Turning both into support could bring $14.931 into focus, representing approximately 81% upside from the chart’s reference price.

But there’s a clear downside condition. A daily close below $6.321 would invalidate the illustrated recovery setup.

For $AVAX, the combination of $AVAX One’s debt elimination and continued buybacks makes an interesting corporate story. Still, the $8.328 reclaim remains the immediate market test, and the $14.931 target needs confirmation rather than optimism.